论文部分内容阅读
目的探讨比索洛尔联合厄贝沙坦治疗慢性心力衰竭的临床疗效。方法选取南宁市第二人民医院五象分院2014年5月—2016年2月收治的慢性心力衰竭患者104例,采取抽签法分为对照组和观察组,各52例。对照组患者给予厄贝沙坦治疗,观察组患者在对照组基础上给予比索洛尔治疗。比较两组患者的临床疗效,治疗前后左心室射血分数(LVEF)、左心室收缩末期内径(LVESd)、左心室舒张末期内径(LVEDd)、超敏C反应蛋白(hsCRP)、B型脑钠肽(BNP)水平及收缩压(SBP)、舒张压(DBP)、脉压差。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者LVEF、LVESd、LVEDd比较,差异无统计学意义(P>0.05);治疗后,观察组患者LVEF高于对照组,LVESd、LVEDd低于对照组(P<0.05)。治疗前,两组患者hs-CRP及BNP水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者hs-CRP及BNP水平低于对照组(P<0.05)。治疗前,两组患者SBP、DBP及脉压差比较,差异无统计学意义(P>0.05);治疗后,观察组患者SBP、DBP及脉压差低于对照组(P<0.05)。结论采用比索洛尔联合厄贝沙坦治疗慢性心力衰竭的临床疗效确切,可有效改善患者心功能,降低hsCRP、BNP水平,稳定血压。
Objective To investigate the clinical efficacy of bisoprolol combined with irbesartan in the treatment of chronic heart failure. Methods 104 cases of chronic heart failure admitted to the Fifth People’s Hospital of Nanning Second People’s Hospital from May 2014 to February 2016 were selected and randomly divided into control group and observation group with 52 cases in each group. Patients in the control group were treated with irbesartan. Patients in the observation group were given bisoprolol on the basis of the control group. The clinical efficacy, LVEF, LVESd, LVEDd, hsCRP and B-type natriuretic peptide in patients before and after treatment were compared between the two groups. Peptide (BNP) levels and systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure difference. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, there was no significant difference in LVEF, LVESd and LVEDd between the two groups (P> 0.05). After treatment, the LVEF in the observation group was higher than that in the control group, LVESd and LVEDd were lower than those in the control group (P <0.05). Before treatment, the levels of hs-CRP and BNP were not significantly different between the two groups (P> 0.05). After treatment, the levels of hs-CRP and BNP in the observation group were lower than those in the control group (P <0.05). Before treatment, there was no significant difference in SBP, DBP and pulse pressure difference between the two groups (P> 0.05). After treatment, the SBP, DBP and pulse pressure difference in the observation group were lower than those in the control group (P <0.05). Conclusion Bisoprolol combined with irbesartan in the treatment of chronic heart failure has definite curative effect, which can effectively improve the cardiac function, reduce the levels of hsCRP and BNP, and stabilize the blood pressure.